Ethical and Scientific Issues in Studying the Safety of Approved Drugs

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

PAPERBACK
price:$55.00
add to cart

Rights & Permissions

Free PDF Access

Free Resources

Related Titles

The Future of Drug Safety: Promoting and Protecting the Health of the Public
Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
Other Related Titles

Ethical and Scientific Issues in Studying the Safety of Approved Drugs (2012)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Institute of Medicine. "4 Selection and Oversight of Required Postmarketing Studies." Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington, DC: The National Academies Press, 2012.

Please select a format:

Page
211


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Ethical and Scientific Issues in Studying the Safety of Approved Drugs

Schluger, N. W. 2008. Improving protection for human research subjects: Better oversight, not just more oversight. American Journal of Bioethics 8(11):13-15.

Stang, P. E., P. B. Ryan, J. A. Racoosin, J. M. Overhage, A. G. Hartzema, C. Reich, E. Welebob, T. Scarnecchia, and J. Woodcock. 2010. Advancing the science for active surveillance: Rationale and design for the observational medical outcomes partnership. Annals of Internal Medicine 153(9):600-606.

Stolberg, H. O., G. Norman, and I. Trop. 2004. Randomized controlled trials. American Journal of Roentgenology 183(6):1539-1544.

Strom, B.L. 2005. Pharmacoepidemiology, Fourth Edition. John Wiley and Sons: Hoboken, NJ.

Temple, R., and S. S. Ellenberg. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133(6):455-463.

Thiers, F. A., A. J. Sinskey, and E. R. Berndt. 2008. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery 7:13-14.

Truog, R. D., W. Robinson, A. Randolph, and A. Morris. 1999. Is informed consent always necessary for randomized, controlled trials? New England Journal of Medicine 340(10):804-807.

Van Assche, G., M. Van Ranst, R. Sciot, B. Dubois, S. Vermeire, M. Noman, J. Verbeeck, K. Geboes, W. Robberecht, and P. Rutgeerts. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. New England Journal of Medicine 353(4):362-368.

Vandenbroucke, J. P., and B. M. Psaty. 2008. Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA 300(20):2417-2419.

Wadman, M. 2007. Biomedical philanthropy: State of the donation. Nature 447(7142):248-250.

Wendler, D. 2009. Must research participants understand randomization? American Journal of Bioethics 9(2):3-8.

Wittes, J., E. Barrett-Connor, E. Braunwald, M. Chesney, H. J. Cohen, D. DeMets, L. Dunn, J. Dwyer, R. P. Heaney, V. Vogel, L. Walters, and S. Yusuf. 2007. Monitoring the randomized trials of the Women’s Health Initiative: The experience of the Data and Safety Monitoring Board. Clinical Trials 4(3):218-234.